Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

Description

This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.

Conditions

Venous Thromboembolism

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism (VTE) Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial.

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

Condition
Venous Thromboembolism
Intervention / Treatment

-

Contacts and Locations

Miami

University of Miami Hospital, Miami, Florida, United States, 33136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * \> 18 years of age
  • * Planning to undergo a primary total hip or knee arthroplasty
  • * High risk patients for VTE as defined by:
  • * History of venous thromboembolism
  • * Active malignancy
  • * Known pro thrombotic condition
  • * BMI \> 40
  • * Patients requiring anticoagulation for pre-existing conditions
  • * Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others.
  • * Patients not fluent in the language of the informed consent form
  • * Prisoners
  • * Pregnancy
  • * Reported to have mental illness or belonging to a vulnerable population

Ages Eligible for Study

19 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Miami,

Victor Hernandez, MD, PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

2026-03-01